Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis (ACR Convergence 2023) - Sep 24, 2023 - Abstract #1946; Pres time: Nov 14, 2023; 09:00 AM - 11:00 AM; Location: Poster Hall; in person; P2 | "Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases characterized by muscle inflammation and weakness. Zetomipzomib demonstrated a favorable safety and tolerability profile without signs of direct immunosuppression upon prolonged exposure. Zetomipzomib did not show differentiation from placebo, but individual patients with DM or PM experienced a clinically meaningful improvement in TIS. R."
Clinical • Dermatomyositis • Immunology • Infectious Disease • Inflammation • Myositis
|
|
Rohit Aggarwal1; Namita Goyal2; Diana Lam3; Allen Ng3; Richard Leff4; Kathryn Ray3; Eunmi Park3; Noreen Henig3
|